CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value [Seeking Alpha]
CG Oncology, Inc. (CGON)
Company Research
Source: Seeking Alpha
Data from phase 3 BOND-003 study turning out positive, could possibly mean an ability for the company to file a New Drug Application to the FDA in 1st half of 2025. A phase 2 study has been initiated, where the combination of cretostimogene + Keytruda is being used to target high-risk BCG-unresponsive NMIBC patients; Data to be released at ASCO 2024. The global bladder cancer market size is projected to reach $7.52 billion by 2030. CG Oncology, Inc. NASDAQ: CGON reported positive results from its phase 3 BOND-003 study, which used its monotherapy immunotherapy drug known as cretostimogene for the treatment of patients with high-risk BCG-unresponsive non-muscle invasive bladder Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology, Inc. (NASDAQ: CGON) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.MarketBeat
- CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- CG Oncology reports data from Phase 3 bladder cancer study [Seeking Alpha]Seeking Alpha
CGON
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 3
- 5/9/24 - Form 8-K
- CGON's page on the SEC website